TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has provided an announcement.
Hemogenyx Pharmaceuticals announced the exercise of warrants over 250,000 new ordinary shares, resulting in the issuance of equity and receipt of £450,000 in subscription monies. This development will increase the total number of issued shares to 5,293,896, impacting shareholder voting rights and potentially enhancing the company’s financial position as it continues its clinical trials.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded biopharmaceutical company based in London, with operations in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, leveraging distinct product candidates and platform technologies for novel product development.
Average Trading Volume: 77,912
Technical Sentiment Signal: Buy
Current Market Cap: £43.02M
See more insights into HEMO stock on TipRanks’ Stock Analysis page.